PDCD1 and neoplasm: Typically, biomarkers, including PD-L1 expression [4], tumor mutational burden (TMB) [5], DNA mismatch repair (MMR) deficiency [6], and tumor-infiltrating lymphocytes (TILs) [7], have been used to select patients suitable for PD-1 blockade immunotherapy in clinic, but all of them have limited utility.